Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
ARKGvsXPHETF Comparison
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. SPDR S&P Pharmaceuticals ETF (XPH) is part of the US Health Care segment. ARKG's top 3 sector exposures are Health Care and Information Technology. In contrast, XPH's top sector exposures are Health Care ARKG is more expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.35% for XPH. ARKG is down -5.11% year-to-date (YTD) with -$10M in YTD flows. XPH performs worse with -5.13% YTD performance, and +$96M in YTD flows. Run a side-by-side ETF comparison of ARKG and XPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
ARKG vs XPH performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG XPH | -3.62%-6.46% | -10.23%-4.96% | -5.11%-5.13% | +23.23%+26.10% | -2.84%+37.18% | -70.08%+4.53% |
| Flows | ARKG XPH | -$50M+$20M | -$85M+$103M | -$10M+$96M | -$210M+$121M | -$627M+$56M | -$2.79B+$44M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG XPH | +39.15%+21.49% | +44.62%+23.31% | +42.26%+19.10% | +45.19%+20.31% |
| Max drawdown | ARKG XPH | -19.50%-8.79% | -23.94%-17.10% | -51.98%-23.45% | -80.33%-32.89% |
| Max drawdown duration | ARKG XPH | 48d16d | 77d140d | 966d322d | 1822d1703d |
ARKG | XPH | |
Last sale 3/13/2026 at 1:30 PM | $26.36 | $53.25 |
| Previous close 03/12/2026 | $26.17 | $53.64 |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
ARKG | XPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
ARKG | XPH | |
|---|---|---|
| Last price | $26.36 | $53.25 |
| 1D performance | +0.73% | -0.73% |
| AuM | $1.11 B | $308.63 M |
| E/R | 0.75% | 0.35% |
ARKG | XPH | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | SPDR |
| Benchmark | - | S&P Pharmaceuticals Select Industry Index |
| N° of holdings | 30 | 49 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | June 19, 2006 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the ARKG and XPH ETFs performed in 2026?
As of March 11, 2026, ARKG is down -5.11% year-to-date (YTD), while XPH has lost -5.13%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or XPH?
Year-to-date, the ARKG ETF saw -$10M in flows, compared to +$96M for XPH.
Which ETF is more volatile: ARKG or XPH?
Over the past year, ARKG had a volatility of 44.62%, while XPH experienced 23.31%.
Which ETF is bigger: ARKG or XPH?
As of March 11, 2026, ARKG holds $1.11 B in assets under management (AUM), while XPH manages $308.63 M.
What sectors do the ARKG and XPH ETFs invest in?
ARKG leans toward sectors like Health Care. Meanwhile, XPH focuses on Health Care.
What are the top holdings of the ARKG ETF and XPH ETF?
ARKG top holdings include CRISPR THERAPEUTICS, PERSONALIS INC and GUARDANT HEALTH INC. XPH holds in its top three: LIQUIDIA CORPORATION, US55287L1017 and AXSOME THERA CMN STK.
Which ETF is more diversified: ARKG or XPH?
ARKG holds 30 securities with 63.79% of its assets in the top 15. XPH has 57 securities and a top 15 weight of 32.4%.
Donald Trump’s Executive Orders: ETF Bulls and Bears
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
Biotech ETFs – Investing in Health Innovation
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
